Jerrica Farias
Nurse Practitioner · Tampa, FLNPI 1740674480
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by UCB SA at 27.7% of the total. 2025 is the largest year on record at $52,538, more than ten times the $3,154 reported in 2021. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $693.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$35K
- Argenx US, Inc.$28K
- UCB, Inc.$27K
- CSL Behring$21K
- Amylyx Pharmaceuticals, Inc.$11K
- Sanofi$2K
- plus $2K from 6 others
What the payments were for
- Consulting fees$42,53033%
- Speaking & faculty fees$52,13741%
- Travel & lodging$27,99722%
- Food & beverage$4,2563%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 18 | $35,229 |
| Argenx US, Inc. | 42 | $27,585 |
| UCB, Inc. | 55 | $27,375 |
| CSL Behring | 44 | $21,305 |
| Amylyx Pharmaceuticals, Inc. | 4 | $11,337 |
| Sanofi | 3 | $2,458 |
| Sarepta Therapeutics, Inc. | 8 | $615 |
| Johnson & Johnson | 2 | $295 |
| Alnylam Pharmaceuticals Inc. | 2 | $256 |
| AstraZeneca | 2 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $249 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,985 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 54 | $2,127,052 |
| UltomirisRavulizumab-Cwvz | 23 | $1,555,463 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 92 | $1,418,293 |
| Radicava OrsEdaravone | 92 | $1,275,383 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 56 | $1,202,403 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 64 | $891,486 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $333,110 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $298,179 |
| NuedextaDextromethorphan Hbr/Quinidine | 38 | $70,330 |
| Pyridostigmine Bromide | 77 | $9,784 |
| Riluzole | 96 | $9,111 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,234 |
| Gabapentin | 182 | $5,995 |
| Mycophenolate Mofetil | 41 | $5,510 |
| Metaxalone | 14 | $5,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $21,305 | $2,309,779156 claims |
| Argenx US, Inc.Vyvgart | $27,585 | $2,127,05254 claims |
| AstraZenecaUltomiris | $255 | $1,555,46323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $249 | $298,17922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Tampa
- April WessonTampa$342K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Jennifer PuleoTampa$171K
- Melissa CarverTampa$129K
- Sara TinsleyTampa$93K
- Erin ParkinsonTampa$65K
- Michele LaineTampa$58K
- Jana BucknerTampa$58K
- Tiffany TrentTampa$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.